DarioHealth Corp.
NASDAQ:DRIOMedical - Diagnostics & Research
-$0.12 today
- Market cap
- $50.27M
- Beta
- 1.08
- P/E (TTM)
- 5.5
- EPS (TTM)
- $1.26
Volume 0.01M
Average 0.01M
DRIO Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
DarioHealth Corp.NASDAQ: DRIO
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow outflow shrinks to $0
Q1 FY2026 financing cash flow was $0, compared with $6.82M a year earlier. Trailing-twelve-month financing cash flow was $17.5M. Over 3 fiscal years it compounded at -26.8% a year.
Context
- Financing cash flow amounted to 108.7% of revenue in FY2025, down 33.8 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly financing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of $4.37M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 24.31M USD
- Year-over-year change
- -36.9%
- 4-year CAGR
- -22.0%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.31M | -36.9% |
| FY2024 | 2024-12-31 | 38.53M | +111.1% |
| FY2023 | 2023-12-31 | 18.25M | -70.5% |
| FY2022 | 2022-12-31 | 61.94M | -5.8% |
| FY2021 | 2021-12-31 | 65.77M | — |
Financing Cash Flow vs competitors
How DRIO compares with its peers on the latest reported figures
- DRIO's LTM Mar 2026 financing cash flow of $17.5M is the 7th largest of the 11 companies compared; the peer median is $27.27M.
- Its year-over-year change of -30.4% is the 9th highest of 11, against a peer median of +114.8%.
- Financing cash flow amounts to 82.6% of revenue for DRIO, versus a peer median of 11.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $224.57M | +85.0% | +72.0% | 452.9% | |
| LTM Mar 2026 | $108.93M | +421.9% | — | 124.0% | |
| LTM Mar 2026 | $70.71M | +60.2% | +172.5% | 3851.4% | |
| LTM Mar 2026 | $63.96M | +123.6% | +116.0% | 7.7% | |
| LTM Mar 2026 | $48.45M | +266.7% | -42.3% | 15.1% | |
| LTM Mar 2026 | $47.6M | +217.3% | — | 5.7% | |
| LTM Mar 2026 | $17.5M | -30.4% | -26.8% | 82.6% | |
| LTM Mar 2026 | $11.1M | -85.7% | — | 1.6% | |
| LTM Mar 2026 | $8.51M | -38.3% | +44.5% | 0.9% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $6.95M | +2116.1% | — | 71.2% |
| LTM Mar 2026 | $2.91M | +106.1% | -29.1% | 1.8% | |
| Peer median (excluding DRIO) | $27.27M | +114.8% | +58.3% | 11.4% | |
Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (76.76M) | (62.19M) | (59.43M) | (42.75M) | (41.71M) |
| Depreciation & Amortization | 4.46M | 4.72M | 4.99M | 7.43M | 2.83M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.97M | 16.98M | 19.7M | 15.8M | 9.37M |
| Change in Working Capital | (2.57M) | (10.9M) | 4.07M | (2.47M) | 2.21M |
| Accounts Receivables | (367K) | (5.11M) | 2.84M | 1.6M | 2.64M |
| Inventory | (2.23M) | (1.73M) | 2.89M | 308K | 437K |
| Accounts Payables | 1.08M | (2.79M) | (1.19M) | (496K) | (122K) |
| Other Working Capital | (1.06M) | (1.28M) | (464K) | (3.88M) | (752K) |
| Other Non-Cash Items | (503K) | 3.56M | 288K | (16.57M) | 1.37M |
| Operating Cash Flow | (50.41M) | (47.85M) | (30.38M) | (38.56M) | (25.94M) |
| Capital Expenditures | (261K) | (573K) | (584K) | (138K) | (142K) |
| Acquisitions (Net) | (7.47M) | 0 | 0 | (8.8M) | 0 |
| Purchases of Investments | 0 | 0 | (5M) | 0 | (4.2M) |
| Sales of Investments | 0 | 0 | 5.03M | 0 | 0 |
| Other Investing Activities | (400K) | (131K) | 0 | 0 | 0 |
| Investing Cash Flow | (8.13M) | (573K) | (547K) | (8.93M) | (4.34M) |
| Debt Repayment | 0 | 23.79M | 1.77M | 0 | 185K |
| Common Stock Issued | 64.88M | 38.29M | 1.61M | 0 | 24.13M |
| Common Stock Repurchased | 0 | (134K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 889K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 65.77M | 61.94M | 18.25M | 38.53M | 24.31M |
| Effect of Forex Changes | 0 | 0 | 0 | (68K) | 9K |
| Net Change in Cash | 7.22M | 13.52M | (12.67M) | (9.03M) | (5.96M) |
| Free Cash Flow | (50.67M) | (48.42M) | (30.96M) | (38.7M) | (26.08M) |
DarioHealth Corp.
NASDAQ:DRIO
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.